Communiqués Lyell Immunopharma, Inc.

Actions

LYEL

US55083R1041

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/06/2024			Varia. 5j.	Varia. 1 janv.
2,59 ^USD	+1,17 %		+4,44 %	+33,51 %

06/05	Mise à jour sectorielle : Les actions du secteur de la santé en hausse en fin d'après-midi	MT
06/05	Les actions de Lyell Immunopharma augmentent après la réduction de la perte nette du premier trimestre	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference	03/06	GL
Lyell Immunopharma to Participate in BofA Securities Health Care Conference	07/05	GL
Lyell Immunopharma: Q1 Earnings Snapshot	06/05	AQ
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024	06/05	GL
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting	05/03	GL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023	28/02	GL
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02	GL
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02	AQ
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference	03/01	GL
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma	09/11	GL
Lyell Immunopharma: Q3 Earnings Snapshot	07/11	AQ
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023	07/11	GL
SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors	04/11	PU
SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time	03/11	PU
SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming	03/11	PU
SITC 2023: Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies	03/11	PU
SITC 2023: Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors	03/11	PU
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing	31/10/23	GL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	27/09/23	GL
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting	27/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Lyell Immunopharma, Inc.

Actions

LYEL

US55083R1041

Communiqués

Filtres